RA Capital Acquires Up to 10% Stake in Gene Therapy Biotech

According to a recent filing by Solid Biosciences Inc. (NASDAQ: SLDB), RA Capital Management, L.P. and affiliated investors expanded their position by net purchasing approximately 3.15 million shares on the open market between March 11 and 17, 2026. Including shares issuable upon conversion of pre-funded warrants, their voting stake on a common-stock basis rose to as much as 9.9%. The acquisition amounted to roughly $23.7 million (about KRW 32 billion). The filing stated the shares are held for investment purposes through funds and accounts managed by RA Capital, with no plans to seek management participation or exert control.

Earlier this month, the company completed a private placement raising about $240 million (around KRW 320 billion) from institutional investors, meeting Nasdaq’s minimum bid price requirement and providing substantial capital. Solid Biosciences also plans a follow-up meeting with the U.S. Food and Drug Administration in the first half of this year to discuss the potential accelerated approval of its lead Duchenne muscular dystrophy (DMD) gene therapy candidate, SGT-003.

Solid Biosciences is a U.S. clinical-stage biotechnology company developing AAV-based gene therapies for rare neuromuscular and cardiac diseases, including DMD. It is expanding its pipeline into high-risk rare indications such as Duchenne muscular dystrophy and Friedreich’s ataxia. Given the large-scale clinical trials and long-term development costs in gene therapy, participation from specialized biotech investors like RA Capital often serves as a critical funding mechanism.